Pharmacokinetics of mequindox and one of its major metabolites in chickens after intravenous, intramuscular and oral administration

Research in Veterinary Science

Volumn 93, Issue 1, 2012, Pages 374-377

  Ding, Huanzhong ^a   Liu, Yingchun ^b   Zeng, Zhenling ^a   Si, Hongbin ^a   Liu, Kaiyong ^a   Liu, Yiming ^a   Yang, Fan ^a   Li, Yafei ^a   Zeng, Dongping ^a  

^a SOUTH CHINA AGRICULTURAL UNIVERSITY   (China)

^b Shanghai Veterinary Research Institute   (China)

Author keywords

Chickens; Mequindox; Metabolite; Pharmacokinetics

Indexed keywords

ANTIINFECTIVE AGENT; DRUG METABOLITE; MEQUINDOX; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CHICKEN; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG TRANSFORMATION; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; SINGLE DRUG DOSE; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ANIMALS; CHICKENS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; INJECTIONS, INTRAMUSCULAR; INJECTIONS, INTRAVENOUS; QUINOXALINES;

GALLUS GALLUS;

EID: 84861483058     PISSN: 00345288     EISSN: 15322661     Source Type: Journal    
DOI: 10.1016/j.rvsc.2011.07.007     Document Type: Article

References (21)

1. Botsoglou B.A., Fletouris D.J. Drug Residues in Foods Pharmacology, Food Safety, and Analysis 2001, Marcel Dekker, New York, Chapter 6.
2. Chen Q., Tang S.S., Jin X., Zou J.J., Chen K.P., Zhang T., Xiao X.L. Investigation of the genotoxicity of quinocetone, carbadox and olaquindox in vitro using Vero cells. Food and Chemical Toxicology 2009, 47:328-334.
3. Charman W.N., Rogge M.C., Boddy A.W., Boddy A.W., Barr W.H., Berger B.M. ) Absorption of danazol after administration to different sites of the gastrointestinal tract and the relationship to single- and double-peak phenomena in the plasma profiles. Journal of Clinical Pharmacology 1993, 33:1207-1213.
4. Gibaldi M., Perrier P. Pharmacokinetics 1982, Marcel Dekker, New York. second ed.
5. Gramatte T., EL-Desoky E., Klotz U. Site-dependent small intestinal absorption of ranitidine. European Journal of Clinical Pharmacology 1994, 46:253-259.
6. Huang L.L., Wang Y.L., Tao Y.F., Chen D.M., Yuan Z.H. Development of high performance liquid chromatographic methods for the determination of cyadox and its metabolites in plasma and tissues of chicken. Journal of Chromatography B 2008, 874:7-14.
7. Huang Y.Q., Li Y.Q., Yang Y.J., Miao X.L., Xie Y., Bai D.Y., Lu C.W., Sun L., Ma B.Z. Studies on the pharmacokinetics of Mequindox in sheep. Journal of Northwest A & F University Nat. Sci. Ed. 2008, 36(2):77-81. (In Chinese).
8. Hutchinson M.J., Young P.B., Kennedy D.G. Confirmation of carbadox and olaquindox metabolites in porcine liver using liquid chromatography-electrospray, tandem mass spectrometry. Journal of Chromatography B 2005, 816:15-20.
9. Kesiūnaité G., Naujalis E., Padarauskasa A. Matrix solid-phase dispersion extraction of carbadox and olaquindox in feed followed by hydrophilic interaction ultra-high-pressure liquid chromatographic analysis. Journal of Chromatography. A 2008, 1209:83-87.
10. Lennernas H., Regardh C.G. Evidence for an interaction between the beta-blocker pafenolol and bile salts in the intestinal lumen of the rat leading to dose-dependent oral absorption and double-peaks in the plasma concentration-time profile. Pharmaceutical Research 1993, 10:879-883.
11. Lipka E., Lee I.D., Langguth P., Spahn-Langguth H., Mutschler E., Amidon G.L. Celiprolol double-peak occurrence and gastric motility: nonlinear mixed effects modeling of bioavailability data obtained in dogs. Journal of Pharmacokinetics and Biopharmaceutics 1995, 23:267-286.
12. Liu Y.C., Si H.B., He L.M., Ding H.Z., Huang X.H., Chen J.X., Chen Z.L., Zeng Z.L. identification mequindox and its metabolites by high performance liquid chromatography combined with ion trap/time-of-flight mass spectrometry. Chinese Journal of Analytical Chemistry 2010, 38:82-86. (in Chinese).
13. Lu C.W., Li Y.Q., Guan Y.J., Zhang Y.B., Bai D.Y., Miao X.L., Xiong Y.J. Pharmacokinetics of mequindox in rabbits with experimental hepatic injury. Journal of Northwest A&F University Nat. Sci. Ed. 2008, 36(12):29-34. (in Chinese).
14. Mostafavi S.A., Foster R.T. Influence of cimetidine coadministration on the pharmacokinetics of acebutolol enantiomers and its metabolite diacetolol in a rat model: the effect of gastric pH on double-peak phenomena. International Journal of Pharmaceutics 2003, 255:81-86.
15. Oberle R.L., Amidon G.L. The influence of variable gastric emptying and intestinal transit rates on the plasma level curve of cimetidine; an explanation for the double peak phenomenon. Journal of Pharmacokinetics and Biopharmaceutics 1987, 15:529-544.
16. Plusquellec Y., Campistron G., Staveris S., Barre J., Jung L., Tillement J.P., Houin G. A double-peak phenomenon in the pharmacokinetics of veralipride after oral administration: a double-site model for drug absorption. Journal of Pharmacokinetics and Biopharmaceutics 1987, 15:225-239.
17. Roberts M.S., Magnusson B.M., Burczynski F.J., Weiss M. Enterohepatic circulation: physiological, pharmacokinetic and clinical implications. Clinical Pharmacokinetics 2002, 41:751-790.
18. Sin D.W.M., Chung L.P.K., Lai M.M.C., Siu S.M.P., Tang H.P.O. Determination of quinoxaline-2-carboxylic acid, the major metabolite of carbadox, in porcine liver by isotope dilution gas chromatography-electron capture negative ionization mass spectrometry. Analytica Chimica Acta 2004, 508:147-158.
19. Wang Y.X., ROY A., Sun L., Lau C.E. A double-peak phenomenon in the pharmacokinetics of alprazolam after oral administration. Drug Metabolism and Disposition 1999, 27:855-859.
20. Weitschies W., Bernsdorf A., Giessmann T., Zschiesche M., Modess C., Hartmann V., Mrazek C., Wegner D., Nagel S., Siegmun W. The talinolol double-peak phenomenon is likely caused by presystemic processing after uptake from gut lumen. Pharmaceutical Research 2005, 22:728-735.
21. Yin O.Q.P., Tomlinson B., Chow A.H.L., Chow M.S.S. A modified two-portion absorption model to describe double-peak absorption profiles of ranitidine. Clinical Pharmacokinetics 2003, 42:179-192.